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ABSTRACT
Despite a growing number of descriptive studies
that show Single-minded 2 (Sim2) is not only
essential for murine survival, but also upregulated
in colon, prostate and pancreatic tumours, there is a
lack of direct target genes identified for this basic
helix–loop–helix/PAS transcription factor. We have
performed a set of microarray experiments aimed at
identifying genes that are differentially regulated by
SIM2, and successfully verified that the Myomesin2
(Myom2) gene is SIM2-responsive. Although SIM2
has been reported to be a transcription repressor,
we find that SIM2 induces transcription of Myom2
and activates the Myom2 promoter sequence when
co-expressed with the heterodimeric partner pro-
tein, ARNT1, in human embryonic kidney cells.
Truncation and mutation of the Myom2 promoter
sequence, combined with chromatin immunopreci-
pitation studies in cells, has lead to the delineation
of a non-canonical E-box sequence 5’-AACGTG-3’
that is bound by SIM2/ARNT1 heterodimers.
Interestingly, in immortalized human myoblasts
knock down of Sim2 results in increased levels of
Myom2 RNA, suggesting that SIM2 is acting as a
repressor in these cells and so its activity is likely to
be highly context dependent. This is the first report
of a direct SIM2/ARNT1 target gene with accom-
panying analysis of a functional response element.
INTRODUCTION
The Single-minded 2 (SIM2) protein is a member of
the basic helix–loop–helix/Per-Arnt-Sim homology
(bHLH/PAS) group of transcriptional regulators that
are characteristically involved in mediating a variety of
developmental events such as angiogenesis, neurogenesis
and tracheal formation, and cellular responses to environ-
mental stimuli including hypoxia, toxic pollutants and the
light/dark cycle (1–3). Similar to most bHLH/PAS family
members, both of the murine Single-minded genes (Sim1
and Sim2) are essential for post-natal survival in mice.
(4–6). Their Drosophila homologue, dSim, encodes a
positively acting, master regulator of central nervous
system (CNS) midline development (7–10). As with dSIM,
SIM2 appears to have key neurological functions. Sim2 is
expressed in brain regions where it is required to produce a
full complement of anterior hypothalamic cells expressing
thyrotropin-releasing hormone and somatostatin (11,12)
and for the correct development of mammillary body
neurons (13). The Sim2 homozygous mutant phenotype,
however, is complex and not immediately informative.
Sim2
 /  mice die soon after birth due to a breathing defect
involving abnormal rib protrusions that attach aberrantly
to intercostal muscle, a hypoplastic diaphragm and even-
tual tears in the pleural mesothelium (5). The majority of
mutant mice also develop congenital scoliosis associated
with asymmetric rib growth and a second group has
reported additional secondary palatal closure and cranio-
facial defects in Sim2 mutant mice on a slightly diﬀerent
genetic background (5,6). Extensive in situ hybridization
experiments have identiﬁed a tissue-speciﬁc pattern of
Sim2 transcript expression in the diencephalon, kidney,
craniofacial structures, limbs, ribs and skeletal muscle of
the developing mouse that is maintained in the adult, with
highest expression in the kidneys, skeletal muscle and
brain (5,14–18). Interestingly, the location of the human
Sim2 gene (hSim2) in the Down syndrome critical region
of the human genome, coupled with learning defects found
in mice overexpressing Sim2 (19,20), suggest it may play
some role in the complex aetiology of Down syndrome.
Despite this impressive array of descriptive data there
remains a deﬁcit of mechanistic, functional analysis of the
SIM2 protein.
Group I members of the bHLH/PAS family (including
SIM2) are usually signal or spatiotemporally induced and
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tein, in order to recognize their cognate DNA element and
aﬀect transcription of target genes. Unlike the majority
of bHLH/PAS factors that contain strong transactiva-
tion domains (including dSIM), the murine Sim2 gene
product is a potent repressor of transcription in mamma-
lian one-hybrid experiments (21). Whilst the native SIM2/
ARNT DNA response element has yet to be elucidated,
the dSIM/dARNT complex recognizes CNS midline
enhancer elements [CME, 50-(G/A)(T/A)ACGTG-30]
often present in multiple copies in target genes (22).
Expression of a short isoform of mammalian SIM2 or
truncation mutants, in which the C-terminal repression
regions of SIM2 have either been totally removed or
replaced with aconstitutive transactivation domain, results
in activation of CME-driven reporter genes in transient
transfection assays in mammalian cells (23–25). The SIM2/
ARNT heterodimer has also been shown to bind hypoxic
response element (HRE, 50-TACGTG-30) sequences in a
reporter gene context in cells (26) and so a reasonable
prediction is that direct target genes of SIM2 will contain
hexameric sequences that are identical or very similar to
the core 50-ACGTG-30 sequence found in CME and HRE
sequences.
Interestingly, the short isoform of hSIM2 (hSIM2s) has
been shown to be expressed selectively in colon, prostate
and pancreatic carcinomas but not in corresponding
normal tissues (27,28). This hSim2s splice variant encodes
a 570 amino acid protein (29) that contains only one of the
two SIM2 repression regions and a unique C-terminal
sequence of 44 residues. More excitingly, antisense
inhibition of hSim2s results in inhibition of cancer cell
growth and induction of apoptosis, leading to speculation
that it may be a useful tumour marker and possible
therapeutic target (28,30). While most attention has
focused on the upregulation of hSim2s, transcripts
encoding the long isoform of hSim2 (hSim2) have also
been detected selectively in pancreatic tumours and cell
lines but not in normal tissue (28). Conversely, hSim2s
expression has been reported to be higher in normal breast
epithelium and cell lines than breast tumour tissue and
derived cell lines, indicating that this misregulation may be
tissue-type speciﬁc (31). Despite the fundamental biologi-
cal roles of the SIM proteins and apparent misregulation
in speciﬁc tumour types, extremely little is known of their
mechanisms of action. In an eﬀort to elucidate the
function of SIM2, we show that the transcription factor
is nuclear localized in adult mouse skeletal muscle and we
have used a microarray approach to identify SIM2-
responsive transcripts. From this list of potential SIM2
targets, we analyse the muscle and kidney expressed
Myomesin2 (Myom2) in greater detail, uncovering a non-
canonical E-box sequence, 50-AACGTG-30, as a SIM2/
ARNT binding site in the Myom2 promoter. Interestingly,
although this non-canonical E-box sequence contains the
core HRE sequence, it is rarely found in hypoxia inducible
genes, and consistent with this observation the Myom2
promoter is not induced by HIF-1a/ARNT1. Surprisingly,
given the repressive behaviour of SIM2 in several
transcriptional assays (14,21), the long and short isoforms
of SIM2 activate transcription of the Myom2 promoter
with ARNT1 in human embryonic kidney cells. However,
knockdown of Sim2 in immortalized human myoblasts
leads to an increase in Myom2 levels. This suggests that
SIM2 can regulate transcription of target genes, either
positively or negatively, in a context-speciﬁc manner. This
is the ﬁrst report of an endogenous SIM2/ARNT response
element in a bona ﬁde direct target gene identiﬁed for
SIM2.
MATERIALS & METHODS
Construction ofexpression and reporter vectors
The entire hSim2s cDNA sequence was ampliﬁed in three
segments from cDNA derived from HEK293 cells using
primers SIM2-1 (50CTA AGC TAG CAT GAA GGA
GAA GTC C) with SIM2-184 (50GTG GAT GAC CTT
GTA TCC) for fragment 1, SIM2-149F (50CTG CTC CAA
GAG TAC GAG) with SIM2-480R (50CTC AGG AAA
AAG CGT GCC) for fragment 2 and SIM2-456F (50AAA
AGC CAA TGT TGC CGG) with hSIM2sEcoRV-R
(50GAC TGA TAT CCT TAG AAG CAG AAA GAG G)
for fragment 3. Fragment 1 digested with NheI/BstBI
and fragment 2 digested with BstBI/BamHI were inserted
into NheI/BamHI digested pEF/mSIM2(Myc)2/IRESpuro
(26). The NheI/BamHI fragment from this vector and
fragment 3 digested with BamHI/EcoRV were ligated
into NheI/EcoRV digested pEF/mSIM2(Myc)2/IRESpuro
to produce a mammalian expression vector for Myc-
epitope tagged short form of hSim2, pEF/hSIM2s(Myc)2/
IRESpuro. pEF/hARNT1/bos and pEF/hARNT1/
IRESneo were generated by insertion of the untagged
human ARNT1 cDNA BamHI fragment from
pGEM7Arnt into BamHI digested pEF-bos-cs (32), or
linearised pEF/IRESneo (M.Kleman). A bacterial expres-
sion vector for thioredoxin/6xHis (trx/His) tagged murine
SIM2 (residues 1–231) was generated by PCR ampliﬁca-
tion of Sim2 cds to include an in frame 50 EcoRI site and
30 stop codon with XhoI site and insertion of this fragment
into EcoRI/XhoI digested pET-32a (Novagen, Gibbstown,
NJ, USA). The pMyom2_1.3kb-LUC vector was gener-
ated by PCR ampliﬁcation of a 1.3kb fragment of human
genomic DNA sequence corresponding to the human
Myom2 promoter region ( 1178/+149) and insertion into
SmaI/XhoI digested pGL3-Basic (Promega, Madison, WI,
USA). Directed mutagenesis of this reporter at
Site1 (50AACGTG03t o5 0AAAAAG03) generated
pMyom2_1.3kb_Site1mut-LUC, Site 2 (50AACGTG03t o
50AAAAAG03) pMyom2_1.3kb_Site2mut-LUC and both
sites pMyom2_1.3kb_Site1&2mut-LUC. Sequential trun-
cation of the Myom2 promoter produced 1(  695/
+149), 2(  245/+149), 3(  151/+149) and 4(  91/
+149) by PCR ampliﬁcation of the relevant sections of the
Myom2 promoter and subsequent subcloning into KpnI/
XhoI digested pGL3-Basic (Promega). The pHGTD-
PBasic-LUC plasmid containing 733bp of the HGTD-P
promoter was generated as described for HGTD-P-luc-2
(33),except thatthepromoter fragment was cloned intothe
pGL3-Basic vector (Promega). All other expression or
reporter vectors have been previously described (26,34).
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Generation and propagation of the 293TControl,
293TSIM2 and 293TSIM2/AD cell lines used has been
previously described (26). Labelled cDNA samples derived
from RNA samples from each of the 293T stable cell lines
were hybridized in a pairwise fashion to slides printed with
the 8000 clone human Research Genetics cDNA library.
Each comparison was replicated and each duplicate com-
parison performed with a dye swap to allow correction
for dye labelling biases, resulting in four separate com-
parisons (i.e. four slides). Each replicate was sepa-
rately reverse transcribed and labelled, following the
microarray experimental procedure outlined at http://
www.microarray.adelaide.edu.au/. Good consistency was
observed between replicate spots containing the same
clone on the same slide, between slides replicated with the
same dye pairing and between slides hybridized with dye
swapped samples. Statistical analysis of normalized micro-
array data involved the use of Spot (http://experimental.
act.cmis.csiro.au/Spot/index.php) and a statistics and
graphical package R (http://www.r-project.org/) in com-
bination with a data analysis package, LIMMA (http://
bioinf.wehi.edu.au/limmaGUI/index.html#Rpkgs).
Cellculture andproduction ofdouble stable cell lines
expressing SIM2 orhSIM2s and ARNT1
Human embryonic kidney 293a or 293T cells were
routinely maintained at 378C, 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS)
(JRH Biosciences, Lenexa, KS, USA). To produce stably
transfected polyclonal lines, subconﬂuent 293a cells were
transfected with blank pEF/IRESpuro, or pEF/
SIM2(Myc)2/IRESpuro or pEF/hSIM2s(Myc)2/
IRESpuro with pEF/IRESneo or pEF/hARNT1/
IRESneo, respectively and transfected cells were selected
and expanded with up to 10mg/ml puromycin (Sigma,
St. Louis, MO, USA) and 1mg/ml G418 (Sigma).
Immortalized human myoblast cell line, LHCN-M2, was
cultured to conﬂuency in growth medium as described (35).
At conﬂuency (Day 1), medium was changed to growth
media without hepatocyte growth factor and with 20nM
dexamethasone, 0.5% FBS and 10mg/l insulin and
550mg/l transferrin to induce fusion of the cells. Cells
were transfected with 10nM control siRNA or siRNAs
targeting Sim2 or Myom2 (Ambion, Austin, TX, USA)
using HiPerfect on days 1 and 4 as per the manufacturer’s
instructions (Qiagen, Valencia, CA, USA). By Day 7,
multinucleate cells were present in the culture at low
frequency ( 10% of cells) and cells were not yet fully
elongated or fully diﬀerentiated into myotubes.
Immunofluorescence
Fresh-frozen adult mouse hind limb muscle tissue samples
were sectioned using a cryostat at  208C, 8mm sections
collected on SuperFrost Plus slides (Menzel-Glaser,
Portsmouth, NH, USA) and immediately ﬁxed in freshly
prepared 4% paraformaldehyde for 6min at room
temperature. Sections were washed three times in 50mM
Tris–HCl (pH 7.5), 150mM NaCl, 0.1% Triton X-100
(TBST) for 5min and then blocked by incubation with
10% FBS in TBST for 1–3h at room temperature.
Following this, sections were incubated overnight at
48C in a humid chamber with goat anti-hSIM2 (sc-8716,
lot C1505, Santa Cruz Biotechnology, Santa Cruz, CA,
USA, 1:50), rabbit anti-mouse MYOM1-EH (R2-a-
moEH, 1:1000), mouse anti-mouse MYOM2 (AA259,
1:2) or anti-hSIM2 and anti-mouse MYOM2 or anti-
myogenin (Chemicon, Billerica, MA, USA, 1:100) anti-
bodies together, all diluted in 10% FBS in TBST. After
washing three times in TBST for 5min, sections were
incubated with the following secondary antibodies diluted
1:1000 in 10% FBS/TBST with bisBenzimide H stain
for 1h at room temperature in a dark container; donkey
anti-goat Alexa Fluor 594 (Invitrogen), goat anti-mouse
IgA-FITC (Sigma) or donkey anti-rabbit Alexa Fluor
488 (Invitrogen). Secondary incubations for sections
co-stained for SIM2 and MYOM2 or SIM2 and myogenin
were performed sequentially, with the donkey anti-goat
Alexa Fluor 594 ﬁrst and the goat anti-mouse IgA-FITC
second with three, 5min TBST washes in between. Sections
were subsequently washed three times in TBST, mounted
in Vectashield media (Vector, Burlingame, CA, USA) or
SlowFade mountant (Invitrogen) and examined using a
Nikon Eclipse E800 microscope.
RNA expression analysis
Total RNA from adult mouse tissues or lines was
prepared using RNAwiz reagent (Ambion) or RNABee
(Teltest, Friendswood, TX, USA) according to the
manufacturer’s instructions with an additional DNAse
treatment step to prevent genomic DNA contamination of
samples. Each RNA sample (1mg) was reverse transcribed
using Superscript and the resulting cDNA samples PCR
ampliﬁed using primers or primer/probe sets (Applied
Biosystems, Foster City, CA, USA) speciﬁc for Sim2,
Myom2 and the control GAPDH.
Immunoblotting
Nuclear extracts were prepared as previously described
(36), whilst whole-cell lysates were generated using passive
lysis buﬀer in accordance with the manufacturer’s instruc-
tions for luciferase reporter studies (Promega). Lysates
were subjected to SDS–PAGE (7.5% gel) and then trans-
ferred to nitrocellulose using a semidry blotter (Biorad,
Hercules, CA, USA). Proteins were detected with the
anti-Myc 9E10 or 71D10 monoclonal antibodies (Cell
Signalling) or an anti-ARNT1 rabbit polyclonal serum
raised against residues 1–142 of human ARNT1 (#51).
Luciferase reporter assays
The Myom2 and HGTD-P luciferase reporter plasmids
described above, were used in conjunction with the control
pGL3-Basic-LUC (Promega) vector and the internal
control plasmid pRL-SV40 (Promega). Subconﬂuent
293a or 293T cells were transfected 12–24h after plating
using FuGENE6 (Boehringer Mannheim) as per the
manufacturer’s instructions. Each transfection contained
200ng/well of Fireﬂy Luciferase reporter and 20ng
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5–250ng/well of each expression plasmid or blank expres-
sion plasmid necessary to normalize the amount of DNA
transfected. Cells were lysed in Passive Lysis Buﬀer
(Promega) 48h post-transfection and lysates were analysed
for luciferase activity using the Dual Luciferase Reporter
assay (Promega) according to the manufacturer’s
directions.
Electrophoretic mobility shiftassays
Bacterial expression of thioredoxin/6xHis (trx/His) tagged
ARNT1 (residues 1–362) and partial puriﬁcation using
nickel aﬃnity chromatography has been previously
described (34). Co-expression and isolation of the trx/
His SIM2 (residues 1–231) with trx/His ARNT1 (1–362)
was performed in a similar manner except that cells were
lysed in 20mM sodium phosphate (pH 7.2), 150mM
NaCl, 10mM imidazole and the protein eluting with
250mM imidazole from the nickel aﬃnity column was
immediately desalted using a PD10 column into 20mM
Tris–HCl (pH7.5), 0.1mM EDTA, 10% glycerol, 50mM
NaCl, 0.2mM dithiothreitol. Double stranded, ﬂuores-
cein-labelled DNA probes were composed of the pre-
viously published Ebox sequence (34), or a portion of the
human Myom2 promoter containing the sequence
50-AATCACGATTCAAAACTGGAACGTGTCCTTTC
TGAGTCCC-30 or the mutant Myom2 probe with
sequence 50-AATCACGATTCAAAACTGGAAAAAG
TCCTTTCTGAGTCCC-30 (GeneWorks, Adelaide, SA,
Australia). Binding reaction conditions were identical to
those previously speciﬁed for the HRE probe (34)
containing 1mM PMSF and 8nM FAM-labelled DNA
probe and with pre-immune or a polyclonal antibody
against the N-terminus of ARNT1 (Bambi) added to the
reaction as indicated. Reactions were quickly prepared in
siliconized microfuge tubes and incubated in the dark for
20min at room temperature. Protein/DNA complexes
were resolved on a 7% polyacrylamide, 5% glycerol,
25mM Tris–HCl (pH 8.3), 25mM boric acid and 0.5mM
EDTA gel that had been precooled overnight at 48C and
DNA was visualized with an FX molecular imager
(BioRad).
Chromatin immunoprecipitation assay
Chromatin extracts were prepared from 293 hSIM2s/
ARNT stable cells ( 9 10
6 cells/immunoprecipitation)
as described in the EZ ChIP protocol (Upstate). To
solubilize chromatin and shear DNA, six 10s sonication
pulses interspersed with 20s rest periods were performed
on ice using a Soniﬁer Cell Disruptor 200 (Branson).
Chromatin immunoprecipitation experiments were per-
formed using the EZ ChIP kit (Upstate) as per the
manufacturer’s instructions with 5mg of goat anti-hSIM2
antibody (C15, Santa Cruz Biotech.) or mouse anti-Myc
epitope (4A6, Upstate) for the speciﬁc immunopre-
cipitations and 5mg goat IgG (Santa Cruz Biotech.)
or mouse IgG (Upstate) for the non-speciﬁc controls.
A total of 3ml of eluted DNA was added to each PCR
using primers designed to amplify Myom2 promoter
sequences (Site 1F 50-AAGGATTAGAACTCATG
GAGGAG A-30, Site 1R 50-AGGAAAAGCTTCTTG
TTCAA ACTG-30, Site 3F 50-GCGTCTTTCTCGTA
TCTG ATCTTC-30, Site 3R 50-CTTAAGAAACTCCAC
GTTCTCACA-30) or the control GAPDH primers
included with the EZ ChIP kit (Upstate).
RESULTS
Identification of transcripts differentially regulated by
SIM2in human embryonic kidney cellsusing microarray
technology
In an eﬀort to understand the role of SIM2 in the kidney
and at other sites of expression, we undertook a
microarray-based experiment to identify transcripts that
are diﬀerentially regulated by SIM2. As SIM2 is one of the
few bHLH/PAS family members to act as a repressor in
cell culture experiments (14,21), we made use of the fusion
protein, SIM2/AD, in which the SIM2 repression regions
have been replaced by the constitutive transactivation
domain of the DR, to expedite identiﬁcation of genes that
may be transcriptionally regulated by SIM2. The tran-
script proﬁles from 293T polyclonal stable cell lines
engineered to be control cells or to express SIM2 or
SIM2/AD (26), were examined for diﬀerentially expressed
transcripts by three two-way comparisons between the
diﬀerent cell lines. Many transcripts of interest were
identiﬁed in this manner, particularly those that are
expressed in tissues that also express Sim2, such as the
skeletal muscle transcript Myom2 and those with roles in
tumourigenesis. A list of the top 100 most diﬀerentially
expressed transcripts is supplied (Supplementary mate-
rial). This article focuses on our examination of the




The protein product of Myom2 (MYOM2, also known as
the M-protein) is a 165kDa structural component of
sarcomeric myoﬁbrils (37,38). It belongs to the intracel-
lular group of the immunoglobulin superfamily of proteins
and interacts with the giant protein, TITIN, found in
striated muscles and myosin (39,40). The role of MYOM2
as a structural component of the M-band in striated muscle
has been investigated in detail using electron microscopy
studies, but the expression and function of MYOM2
in other non-muscle tissues has not been examined.
Interestingly, both Sim2 and Myom2 RNAs are detected
in the adult mouse kidney and also in the human embry-
onic kidney cell line, 293a (Figures 2B and 5B).
We have previously shown that SIM2/ARNT1 hetero-
dimers can recognize HRE sequences from the erythro-
poietin (epo) enhancer in a reporter gene context, but
unlike HIF-1a/ARNT1 complexes, do not activate tran-
scription of the reporter in 293T cells (26). As mentioned
earlier, the SIM2/AD fusion protein functions as a
transactivator and has been used as a tool to examine
possible SIM2 target genes. Transfection of the SIM2/AD
chimera clearly activates transcription of the positive
control HRE-reporter in 293T cells (Figure 1). To examine
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transcriptional level, a fragment of the human Myom2
promoter (1.3kb upstream from the transcription start)
was cloned into a luciferase reporter plasmid. Expression
of SIM2/AD activated transcription of this Myom2-
reporter to a higher level than the HRE-reporter
(Figure 1). Potential SIM2/ARNT-binding sites in the
Myom2 promoter region were delineated by sequential
deletion of the promoter fragment in the luciferase
reporter (Figure 1), with reporter activation by SIM2/
AD decreasing gradually as the promoter fragment was
shortened (compare 1 and 2 with pMyom2_1.3kb-
LUC, Figure 1). Signiﬁcantly, there was a marked loss of
activity upon truncation of a 95bp section of promoter
(Figure 1, compare 2 and 3), suggesting that it may
contain SIM2 responsive sites. Sequence analysis of this
fragment identiﬁed a hexameric sequence that is similar,
but not identical to the HRE and CME core consensus
sequence of 50-TACGTG-30. We have termed this Site 1
(50-AACGTG-30).
SIM2/ARNT expression upregulates theendogenous
Myom2 transcript in HEK293a cells
As the Myom2 promoter was induced by expression of the
SIM2/AD chimera, we wished to ascertain the eﬀect of
expression of the wild-type SIM2/ARNT1 heterodimer on
Myom2 transcript levels. As human embryonic kidney
293a cells endogenously express the Myom2 transcript
they were used to generate double stable cell lines
expressing elevated levels of both ARNT1 and SIM2.
Expression of Myc-epitope tagged SIM2 and ARNT1 was
conﬁrmed by western blot analyses of lysates from the
stable cell lines (Figure 2A). Surprisingly, given the
reported role of the SIM2 protein as a transcriptional
repressor, the co-expression of both ARNT1 and SIM2
dramatically increases the level of the endogenous Myom2
transcript, compared to control stable cell lines contain-
ing blank expression vectors or untransfected 293a cells
(Figure 2B).
SIM2/ARNT heterodimers activate transcription from
the human Myom2 promoter through anon-canonical
E-box sequence
Consistent with the change in Myom2 transcript levels in
our 293SIM2/ARNT1 stable cell lines, the Myom2-
reporter is induced with transient co-expression of the
long or short isoform of SIM2 and ARNT1 in 293 cells,
but not with ARNT1 alone (Figure 2C). ARNT1 levels
appear to be limiting in 293 cells as SIM2 alone also
does not activate the Myom2 reporter (Figure 2C).
Co-expression of SIM2 with a truncation mutant of
ARNT1 lacking the C-terminal activation domain,
ARNT1.603, results in abrogation of reporter induction,
showing that the transactivation domain of ARNT1 is
required for this activation of transcription (Figure 2C).
This leads to the proposal that SIM2/ARNT1 hetero-
dimers may operate as activators of Myom2 transcription
by utilizing the ARNT1 transactivation domain.
To test whether the Myom2 promoter Site1 is a
functional SIM2/ARNT1 binding site, we mutated this
site in the Myom2 reporter construct. An identical
50-AACGTG-30 hexameric sequence was found 860bp
upstream of Site1 in the Myom2 promoter, termed Site2,
and this was also independently mutated. Intriguingly,
mutation of Site 1 but not Site 2 resulted in a dramatic
decrease in the induction of this reporter gene by SIM2/
ARNT1 (Figure 2D), suggesting that Site1 is necessary for
SIM2/ARNT1 activation of Myom2 transcription.
Figure 1. Myom2 promoter is induced by SIM2/AD expression. Delineation of required promoter regions and a potential SIM2 responsive site.
Subconﬂuent 293T cells were co-transfected with luciferase reporter plasmids and a blank or SIM2/AD expression plasmid as indicated. After 48h
luciferase activity was assayed and relative luciferase activities normalized to the value for each reporter alone and presented as a fold induction.
Results depicted are from an experiment performed in triplicate with standard deviation, which is representative of four repeats of this set of
transfections.
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To investigate whether the SIM2/ARNT1 heterodimer
could directly recognise DNA sequences found in the
Myom2 promoter, in vitro studies using the EMSA
technique with a 40bp probe sequence from the Myom2
promoter encompassing the Site 1 sequence were per-
formed. Bacterially co-expressed and partially puriﬁed
thioredoxin/6xHis (trx/His) tagged SIM2 (residues 1–231)
and ARNT1 (residues 1–362) formed a complex with the
Myom2 probe that could be speciﬁcally blocked with
an anti-ARNT1 antibody but not the pre-immune serum
(Figure 3, lanes 4–6). This gel-retarded complex did not
form when the partially puriﬁed proteins were mixed with
a probe in which Site1 had been mutated (Figure 3, lane 2,
50-AACGTG-30 mutated to 50-AAAAAG-30). The trx/
His-tagged ARNT1(1–362) protein expressed alone and
partially puriﬁed also forms a shifted complex with the
Myom2 probe; however, this homodimer clearly runs
slightly higher on the non-denaturing gel than the hete-
rodimer and is of much lower intensity (Figure 3, com-
pare lanes 4 and 7). By comparison, the same amount
of partially puriﬁed trx/His-ARNT1(1–362) produces a
much stronger intensity shifted band with its cognate
Figure 2. Expression of the SIM2/ARNT1 heterodimer induces Myom2 transcription in human embryonic kidney cells through a non-canonical
E-box. (A) Nuclear extracts prepared from the 293Control or 293SIM2/ARNT1 cell lines were subjected to SDS–PAGE and western blot using either
anti-ARNT1 polyclonal or anti-Myc monoclonal antibodies. (B) total RNA samples prepared from untransfected 293a cells (lane 1), 293Control
(lane 2) or 293SIM2/ARNT1 (lane 3) double stable cells, were reverse transcribed and the resultant cDNA samples were PCR-ampliﬁed in the linear
range using primers speciﬁc for Sim2, Arnt1, Myom2 and the internal control, GAPDH. Control Myom2 reactions containing RNA samples as
template were also performed (lane 4). C and D, 293 cells were co-transfected for 48h with the Myom2-promoter containing reporter plasmid and
expression vectors as indicated and then assayed for luciferase activity. Luciferase activity was normalized against a Renilla luciferase internal control
and results are depicted as fold induction over the backbone pGL3-Basic-LUC reporter for each transfection. Results shown are either from a single
experiment performed in triplicate with standard deviation, which is representative of four repeats of this set of transfections (C) or from three
independent experiments performed in triplicate with standard deviation (D).
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and puriﬁed trx/His-SIM2 (1–231) and ARNT1 (1–362,
Figure 3, compare lanes 9 and 10). These in vitro
DNA-binding assays are consistent with SIM2/ARNT1
heterodimers recognising the Site1 50-AACGTG-30
sequence in order to regulate the transcription of the
Myom2 gene.
To further support these observations, chromatin
immunoprecipitation experiments were performed using
293a cells engineered to express both ARNT1 and Myc-
epitope tagged hSIM2s. Endogenous Myom2 promoter
DNA containing the Site 1 sequence was highly enriched
in the speciﬁc immunoprecipitation for hSIM2s using an
anti-hSIM2s antibody or an antibody that recognises
the Myc-epitope tag of hSIM2s, compared to the non-
speciﬁc immunoglobulin controls (Figure 4, Site 1 panel,
compare lane 1 with lane 2; lane 3 with lane 4). There was
no enrichment of the control DNA sequences from the
GAPDH gene in the chromatin immunoprecipitation
samples (Figure 4). Likewise, PCR-ampliﬁcation of Site2
in the Myom2 promoter containing an identical core
sequence of 50-AACGTG-30 that is 860bp upstream of
Site 1, did not indicate any enrichment in the hSIM2s
speciﬁc immunoprecipitations at this site (Figure 4). This
conﬁrms that hSIM2s can recognise the Myom2 promoter
in human cells and speciﬁcally binds to DNA at Site 1.
Depletionof Sim2 in cultured human myoblasts affects
endogenousMyom2 transcript levels
The immortalized human myoblast cell line LHCN-M2
was generated by introduction of hTERT and cyclin-
dependent kinase 4 into human satellite cells (35). These
cells express both Sim2 and Myom2 and so we utilized this
cell system to investigate the eﬀect of decreasing Sim2
levels on Myom2 expression in the context of a muscle cell.
LHCN-M2 myoblast cells were transfected with a control
siRNA, either of two independent siRNAs designed to
target Sim2 or an siRNA against Myom2. Knock down of
Sim2 RNA levels with each Sim2 siRNA was observed by
real-time PCR assay 3 days post-siRNA transfection,
compared to treatment with control or Myom2 targeted
siRNAs (Figure 5Ai). This decrease in Sim2 levels was
accompanied by an increase in Myom2 expression after
both a single (Day4) or double (Day7) siRNA treatment
(Figure 5Aii). Thus, Myom2 transcript expression is
becoming derepressed by decreasing Sim2 levels, suggest-
ing Sim2 represses Myom2 expression in LHCN-M2
human myoblasts.
The muscle structural protein Myomesin2 isco-expressed
with SIM2
The expression of Myom2 is regulated through mamma-
lian muscle development. It is transiently expressed in the
very early stages of sarcomerogenesis in cardiomyocytes
and later in skeletal muscle cells, is perinatally down-
regulated and then reappears in adult striated cardiac and
fast ﬁbers only in rodents (41–43). The tight temporal and
spatial expression of the MYOM2 protein appears to
mimic the expression of the transcript (41). Myom2 has
recently been identiﬁed as a transcriptional target of
Myocyte enhancer factor 2 (MEF2) family members (44),
Figure 4. The endogenous Myom2 promoter is bound by SIM2 in
human cells. Chromatin extracts from 293 cells stably expressing
ARNT1 and Myc-epitope tagged hSIM2s were immunoprecipitated
with antibodies recognising hSIM2s (ahSIM2s) or the Myc tag (aMyc)
or an equal amount of the non-speciﬁc immunoglobulin controls (Goat
IgG and Mouse IgG). DNA eluted from the chromatin immunopre-
cipitations was examined by PCR ampliﬁcation using primers designed
to amplify the Site 1 or Site 3 (containing an identical hexamer site to
Site 1 but 850bp upstream) sequences from the Myom2 promoter or
the control GAPDH sequence. Input contains DNA isolated from the
chromatin extract and –ve indicates a control eluate in which no
chromatin extract was added to the immunoprecipitation.
Figure 3. SIM2/ARNT1 dimers recognise the 40bp Myom2 promoter
sequence in vitro. Bacterially co-expressed and partially puriﬁed,
thioredoxin/6xHis tagged N-terminal portions of SIM2 and ARNT1
or ARNT1 alone were bound to ﬂuorescently labelled 40bp Myom2,
Myom2mut or E-box probes and subjected to non-denaturing PAGE.
The presence of ARNT1 in the gel shifted complex was visualized by
incubation with anti-ARNT1 serum (A1) compared to control pre-
immune serum (PI).
3722 Nucleic Acids Research, 2008, Vol. 36, No. 11although control of Myom2 ﬁbre-type speciﬁc expression
remains to be fully elucidated. Contradictory to our data
from cultured human myoblasts, in which SIM2 appears
to be repressing Myom2, at a gross tissue level the Sim2
and Myom2 transcripts appear to be co-expressed in
various adult mouse muscles (with the exception of the
heart, Figure 5B lane 5) by reverse-transcription–PCR.
We wished to address this discrepancy by determining
whether they are co-expressed at a cellular level in normal
tissue. The cellular localization of the SIM2 protein
appears to be constitutively nuclear when the protein is
overexpressed in transformed human cell lines (26,45),
however, the localisation and expression of the endoge-
nous protein has not been examined in normal tissue.
Clear, nuclear localized expression of SIM2 was obvious
throughout sections from adult mouse hindlimb muscle,
but absent in control sections incubated with secondary
antibody alone or with a non-speciﬁc primary (Figure 5C,
D and E iii, data not shown). SIM2 colocalises with a
member of the muscle regulatory factor family, myogenin,
illustrating that SIM2 is indeed found in myonuclei
(Figure 5Ci). Interestingly, given our data that SIM2 can
act both positively and negatively on Myom2 expression in
diﬀerent cell types (46), SIM2 positive nuclei are found
Figure 5. SIM2 represses Myom2 expression in human myoblasts but is coexpressed with MYOM2 in adult mouse muscle. (A) Knockdown of Sim2
in LHCN-M2 myoblasts results in increased Myom2 expression. Level of Sim2 (i) and Myom2 (ii) RNA in LHCN-M2 cells treated with control
(ctrl), Myom2 siRNA (M1) or either of two independent Sim2 siRNAs (S1 and S2) determined by real-time PCR. Experiment is representative of a
set of three repeats, Sim2 and Myom2 expression is relative to GAPDH expression and error bars depict standard deviation. (B) Total RNA samples
prepared from adult mouse muscle tissues (lane 1 abdominal muscle, lane 2 diaphragm, lane 3 forelimb muscle, lane 4 hindlimb muscle, lane 5 heart)
and kidney (lane 6) were reverse transcribed and the resultant cDNA samples were PCR-ampliﬁed in the linear range using primers speciﬁc for Sim2,
Myom2 and the internal control, GAPDH.( C–E) Multiple muscle ﬁbres are presented in the ﬁgure in cross section and each ﬁbre is surrounded by
multiple nuclei. (C) SIM2 is expressed in myonuclei of adult mouse muscle. Composite image (i) of cryostat sections of adult mouse hind limb muscle
immunostained for myogenin (ii) and SIM2 proteins (iii), showing nuclei visualised with bis-Benzimide H (iv). (D) SIM2 is expressed in both
MYOM2 positive and negative muscle ﬁbres. Composite image (i) of cryostat sections of adult mouse hind limb muscle immunostained for MYOM2
(ii, fast ﬁbres) and SIM2 proteins (iii), showing nuclei visualized with bis-Benzimide H (iv). (E) composite image (i) of cryostat sections of adult
mouse hind limb muscle immunostained for EH-MYOM1 (ii, one positive ﬁbre in view) and SIM2 proteins (iii), showing nuclei visualised with
bis-Benzimide H (iv).
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also nuclei surrounding ﬁbres that are not expressing
MYOM2. MYOM2 protein expression predominantly
marks fast ﬁbres in the adult mouse (46), and so SIM2
expression from this colocalisation data is not ﬁbre type
speciﬁc. The Myomesin1 (Myom1) gene is a closely related
homologue of Myom2 and encodes a particular isoform,
EH-MYOM1, that is expressed in a complementary
fashion to MYOM2 in mice (46). SIM2 appears to be
expressed in nuclei surrounding EH-MYOM1 positive
and negative ﬁbres (Figure 5E), consistent with the notion
that SIM2 expression does not appear to be ﬁbre-type
regulated in adult mouse muscle.
Myom2 promoter isspecifically responsive to
SIM2/ARNT1 despite bindingsite similarities
toHRE sequences
Previous experiments have demonstrated that SIM2/
ARNT1 heterodimers can recognise the same HRE
sequences in a reporter construct that are bound by
hypoxically induced HIF-1a/ARNT1 complexes (26).
These experiments utilise reporter constructs containing
4 tandem copies of the 18-nucleotide HRE sequence
from the erythropoietin gene, with the core sequence of
50-TACGTG-30. Given this similarity in possible DNA
recognition motifs between HIF-1a and SIM2 complexes,
the Myom2 promoter was tested for responsiveness to
HIF-1a. While co-expression of HIF-1a and ARNT1 in
293 cells signiﬁcantly induces the hypoxically responsive
pHGTD-P-LUC reporter gene, neither long or short
isoforms of SIM2 with ARNT1 induced transcrip-
tion from this reporter (Figure 6A). In contrast, both
SIM2 isoforms can induce the Myom2-reporter in partner-
ship with ARNT1, whilst co-expression of HIF-1a
and ARNT1 or treatment with the hypoxia mimetic,
2,20-dipyridyl, do not activate the Myom2 promoter
sequence (Figure 6B, data not shown). Use of full-length
promoter constructs rather than truncated, multimerized
binding sites has allowed the elucidation of promoter
choice speciﬁcity between HIF-1a and SIM2 complexes.
DISCUSSION
Despite the suggestion that misregulated SIM2 protein
may play a role in the etiology of Down syndrome and
particular solid tumours, very little is known about its
normal function, mechanism of action and, as yet, there
have been no target genes validated for this transcription
factor with an accompanying description of the functional
SIM2/ARNT1 response element. Surprisingly, whilst the
tissue-speciﬁc expression pattern of Sim2 RNA in the
mouse has been extensively mapped, with predominant
levels in the developing and adult kidneys, brain and
skeletal muscle (5,14–18) the endogenous SIM2 protein
has not been visualised in normal tissue. We demonstrate
here that native SIM2 protein appears to be constitutively
nuclear localized in adult mouse hind limb muscle
(Figure 5). This is consistent with the notion that unlike
other bHLH/PAS family members such as the ubiqui-
tously expressed DR and HIF-1a, SIM2 activity is
controlled by spatiotemporal expression rather than
signal regulated activation (26,47). Whilst there are defects
noted in the formation of one particular muscle (the
diaphragm) in Sim2
 /  mice, the role of Sim2 in other
muscles is not immediately apparent as no obvious
skeletal muscle phenotype is reported for the Sim2
homozygous mutant mice in their limited post-natal life
span (5,6).
In an eﬀort to elucidate the function of the SIM2
protein, we have identiﬁed a host of transcripts that are
diﬀerentially regulated with expression of SIM2 and/or
the chimeric activator SIM2/AD in human embryonic
kidney cells using a microarray screening approach. Given
this large pool of potential SIM2 responsive genes, we
have studied the interaction between SIM2 and transcrip-
tion of the Myom2 gene in greatest detail. Excitingly,
co-expression of SIM2 (long or short) with ARNT1 in 293
Figure 6. The Myom2 promoter is not activated by HIF-1a/ARNT1.
293 cells were cotransfected for 40h with the pHGTD-P-LUC (A)o r
pMyom2_1.3kbBasic-LUC (B) reporter plasmids and expression vectors
as indicated and lysates were assayed for luciferase activity. Luciferase
activity was normalised against a Renilla luciferase internal control and
results are depicted as fold induction over the reporter alone for each
transfection. Results depicted are from a single experiment performed
in triplicate with standard deviation, which is representative of repeats
of this set of transfections.
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by 1.3kb of Myom2 promoter sequence (Figure 2).
This follows on from a recent report showing that the
long and short isoforms of SIM2, in partnership with
ARNT1, can activate transcription from a reporter
driven by Drosophila CME sequences (25). In contrast,
the Myom2-reporter is not induced by expression of
HIF-1a/ARNT1 (Figure 6), and so despite the likelihood
that SIM2 responsive sequences will resemble HRE-like
sequences, this response appears to be SIM2 speciﬁc.
Truncation studies of the 1.3kb Myom2 promoter led to
the identiﬁcation of a 95bp fragment that is primarily,
but not totally, responsible for the induction of this
promoter with SIM2/AD (Figure 1). Informatic analysis
of this 95bp sequence identiﬁed a 6bp sequence termed
Site 1 (50-AACGTG-30) that is highly similar to the core
HRE and CME consensus sequences [50-ACGTG-30].
Mutation of this sequence at both the ARNT1-binding
half site and the partner protein half site (50-AAAAAG-30)
resulted in a dramatically decreased induction of the
1.3kb Myom2 reporter with either SIM2 isoform and
ARNT1 (Figure 2). Mutation of a second possible DNA
binding site (Site 2) had no eﬀect on reporter gene
induction by SIM2/ARNT1 or hSIM2s/ARNT1. In vitro
gel shift assays indicate that the SIM2/ARNT1 dimer
can recognise a 40bp probe derived from the Myom2
promoter containing the Site 1 sequence, but not a mutant
probe in which Site 1 is mutated (Figure 3). Likewise in
cells, Site 1 sequences are enriched in hSIM2s-bound
chromatin (Figure 4). Together these data suggest that
Myom2 is a direct target of SIM2 and that SIM2/ARNT1
heterodimers recognize the Site 1 non-canonical E-box
sequence. This is the ﬁrst report of a bona ﬁde target gene
for SIM2 with an accompanying analysis of the endo-
geous binding site for SIM2. There are likely to be
additional SIM2/ARNT1 binding sites in the 1.3kb
Myom2 fragment studied as truncation of approximately
450bp of promoter sequence preceding the Site 1 sequence
containing one 50-AACGTG-30,a5 0-TACGTG-30 and
three 50-AGCGTG-30 sequences, leads to a decrease in the
induction of the Myom2-reporter with SIM2/AD and
mutation of Site 1 leads to a signiﬁcant, but not total, loss
of induction with hSIM2s/ARNT1 (Figures 1 and 2).
Knockdown of SIM2 in immortalized human myoblasts
leads to an upregulation of Myom2 transcript levels. This
suggests that SIM2 is repressing transcription of the target
Myom2 in cultured human myoblasts and is in con-
cordance with previous reports of SIM2 acting as a potent
transcriptional repressor (21). However, our experiments
in human embryonic kidney cells and those of Metz and
colleagues (25) illustrate the ability of the SIM2/ARNT
heterodimer to also activate transcription. This activation
is dependent on the presence of the ARNT1C-terminal
transactivation domain (Figure 2). This re-emphasises
the common theme of transcription factors being capable
of acting both positively and negatively depending on
cellular context, promoter architecture and DNA binding
site sequences. Indeed during the process of muscle
diﬀerentiation, MEF2 factors initially interact with class
II HDACs and repress target gene expression until activ-
ated by post-translational modiﬁcation at later stages
of muscle diﬀerentiation (48). MYOM2 and SIM2 are
co-expressed in adult hind limb muscle, although unlike
the majority of MYOM2 expression, SIM2 does not
appear to be constrained to fast ﬁbre types as it is also
expressed in nuclei surrounding EH-MYOM1 positive
ﬁbres (Figure 5). Fibre type speciﬁcation is dependent on
the intricate coordination of a number of diﬀerent
pathways involving the hedgehog family members, calci-
neurin signaling and other transcription factors such as
MEF2 family members and the serum response factor,
Oct-1 (44,49–51). Thus whilst the Myom2 promoter is
SIM2-responsive, SIM2 is likely to contribute to Myom2
transcription in partnership with other factors, particu-
larly as consensus MEF2 binding sequences are present in
the Myom2 promoter and MEF2 has been implicated in
controlling ﬁbre type transcriptional programs (41,52).
This article identiﬁes the ﬁrst SIM2/ARNT1 DNA
response element (Site 1 50-AACGTG-30). The deﬁnition
of a consensus SIM2/ARNT1 DNA response element
awaits the veriﬁcation of more target sequences; however,
point mutation of the ﬁrst base of the hexameric sequence
in our reporter system revealed that, while other bases are
also tolerated, an A at position 1 is required for full
activation of the reporter gene (data not shown). It will be
interesting to see whether SIM2, like other bHLH/PAS
proteins, is capable of binding to a variety of similar but
not identical core DNA sequences (41,44,49–51).
Whilst this article was in review, Laﬃn and his
colleagues (53) published a description of hSIM2s as a
transcriptional repressor of the newly identiﬁed target
gene, SLUG. The authors localize hSIM2s binding to a
553 base pair fragment of the SLUG promoter, but do not
deﬁnitively identify the actual site(s) that hSIM2s is recog-
nizing. The sequence contains similar yet not identical
sequences to Site1 (50-AACGTG-30) that we have identi-
ﬁed here. A more detailed analysis of the actual hSIM2s
binding site will be of great interest to enable the deﬁnition
of a consensus SIM2 response element.
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